Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The quick ratio (acid-test) is N/A as of Tuesday, October 6, 2026.
QUICK RATIO (ACID-TEST)
N/A
Electra Therapeutics Inc.
Market Cap
$202.05M
Quick Ratio (Acid-Test)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$192.58M
Quick Ratio (Acid-Test)
7.90
TTM Avg
9.91
3Y Avg
10.86
5Y Avg
18.34
Market Cap
$191.61M
Quick Ratio (Acid-Test)
14.32
TTM Avg
7.65
3Y Avg
9.22
5Y Avg
9.58
Market Cap
$209.42M
Quick Ratio (Acid-Test)
5.26
TTM Avg
3.62
3Y Avg
4.54
5Y Avg
4.95
Market Cap
$213.69M
Quick Ratio (Acid-Test)
5.72
TTM Avg
5.91
3Y Avg
5.85
5Y Avg
7.15
Market Cap
$216.62M
Quick Ratio (Acid-Test)
5.36
TTM Avg
6.17
3Y Avg
11.50
5Y Avg
11.99
Market Cap
$181.64M
Quick Ratio (Acid-Test)
1.41
TTM Avg
1.25
3Y Avg
1.14
5Y Avg
1.20
Market Cap
$178.92M
Quick Ratio (Acid-Test)
15.70
TTM Avg
3.42
3Y Avg
4.67
5Y Avg
3.16
Market Cap
$176.13M
Quick Ratio (Acid-Test)
1.25
TTM Avg
2.29
3Y Avg
3.57
5Y Avg
4.16
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Electra Therapeutics Inc. (ETRA) | $202.05M | N/A | N/A | N/A | N/A |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $192.58M | 7.90 | 9.91 | 10.86 | 18.34 |
| AN2 Therapeutics, Inc. (ANTX)vs › | $191.61M | 14.32 | 7.65 | 9.22 | 9.58 |
| Alector, Inc. (ALEC)vs › | $209.42M | 5.26 | 3.62 | 4.54 | 4.95 |
| Compugen Ltd. (CGEN)vs › | $213.69M | 5.72 | 5.91 | 5.85 | 7.15 |
| Lyell Immunopharma, Inc. (LYEL)vs › | $216.62M | 5.36 | 6.17 | 11.50 | 11.99 |
| Journey Medical Corporation (DERM)vs › | $181.64M | 1.41 | 1.25 | 1.14 | 1.20 |
| Canton Strategic Holdings Inc (CNTN)vs › | $178.92M | 15.70 | 3.42 | 4.67 | 3.16 |
| Cue Biopharma, Inc. (CUE)vs › | $176.13M | 1.25 | 2.29 | 3.57 | 4.16 |
| Compass Therapeutics, Inc. (CMPX)vs › | $176.68M | 11.22 | 14.99 | 15.44 | 13.43 |
Quick Ratio
N/A
Excludes inventory
Current Ratio
N/A
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
